Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-label Study of Adjunctive Ganaxolone (GNX) Treatment in Children and Adults With Tuberous Sclerosis Complex (TSC)-Related Epilepsy (TrustTSC OLE)
Conditions
Interventions
Ganaxolone
Locations
54
United States
Arkansas Children's Research Institute
Little Rock, Arkansas, United States
UCLA Mattel Children's Hospital, TSC Center
Los Angeles, California, United States
Children's Hospital of Orange County
Orange, California, United States
Rady Children's Hospital - San Diego
San Diego, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Nemours Children's Hospital - Delaware Valley
Wilmington, Delaware, United States
Start Date
May 16, 2022
Primary Completion Date
April 2, 2025
Completion Date
April 2, 2025
Last Updated
October 1, 2025
NCT07369505
NCT06879665
NCT06392009
NCT04198181
NCT06975605
NCT06789419
Lead Sponsor
Marinus Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions